Genomma Lab Internacional, S.A.B. de C.V. Logo

Genomma Lab Internacional, S.A.B. de C.V.

GNMLF

(0.2)
Stock Price

1,27 USD

-1.78% ROA

15.66% ROE

14.97x PER

Market Cap.

1.152.600.000,00 USD

60.37% DER

87.45% Yield

9.18% NPM

Genomma Lab Internacional, S.A.B. de C.V. Stock Analysis

Genomma Lab Internacional, S.A.B. de C.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genomma Lab Internacional, S.A.B. de C.V. Fundamental Stock Analysis
# Analysis Rating
1 Dividend

The company's history of regular dividend distributions in the last three years showcases its ability to generate reliable income for shareholders.

2 ROE

Unidentified ROE

3 ROA

Unidentified ROA

4 PBV

Unidentified ROA

5 DER

Unidentified DER

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

Unidentified Graham Number

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genomma Lab Internacional, S.A.B. de C.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Genomma Lab Internacional, S.A.B. de C.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genomma Lab Internacional, S.A.B. de C.V. Revenue
Year Revenue Growth
2015 639.360.087
2016 549.295.439 -16.4%
2017 617.333.725 11.02%
2018 598.889.955 -3.08%
2019 673.209.595 11.04%
2020 696.100.373 3.29%
2021 754.095.876 7.69%
2022 862.356.888 12.55%
2023 969.477.492 11.05%
2024 1.014.399.120 4.43%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genomma Lab Internacional, S.A.B. de C.V. Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genomma Lab Internacional, S.A.B. de C.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 5.665.985.000 100%
2021 6.570.309.000 13.76%
2022 6.922.313.000 5.09%
2023 6.838.185.000 -1.23%
2024 146.226.556 -4576.43%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genomma Lab Internacional, S.A.B. de C.V. EBITDA
Year EBITDA Growth
2015 2.864.496
2016 13.286.022 78.44%
2017 131.284.454 89.88%
2018 115.165.331 -14%
2019 127.968.227 10%
2020 155.219.241 17.56%
2021 154.213.260 -0.65%
2022 180.990.226 14.79%
2023 204.939.341 11.69%
2024 667.368.416 69.29%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genomma Lab Internacional, S.A.B. de C.V. Gross Profit
Year Gross Profit Growth
2015 413.821.991
2016 368.768.148 -12.22%
2017 411.515.678 10.39%
2018 390.151.723 -5.48%
2019 421.294.535 7.39%
2020 431.009.962 2.25%
2021 465.651.237 7.44%
2022 521.085.055 10.64%
2023 593.624.732 12.22%
2024 649.376.816 8.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genomma Lab Internacional, S.A.B. de C.V. Net Profit
Year Net Profit Growth
2015 -61.867.455
2016 -81.592.359 24.17%
2017 65.380.797 224.8%
2018 56.335.750 -16.06%
2019 40.482.048 -39.16%
2020 70.437.529 42.53%
2021 63.682.659 -10.61%
2022 71.224.437 10.59%
2023 60.675.338 -17.39%
2024 137.739.328 55.95%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genomma Lab Internacional, S.A.B. de C.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genomma Lab Internacional, S.A.B. de C.V. Free Cashflow
Year Free Cashflow Growth
2015 -8.623.886
2016 60.125.525 114.34%
2017 34.674.810 -73.4%
2018 -24.000.802 244.47%
2019 -25.216.956 4.82%
2020 30.399.287 182.95%
2021 13.543.826 -124.45%
2022 63.647.142 78.72%
2023 74.429.599 14.49%
2024 7.454.356 -898.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genomma Lab Internacional, S.A.B. de C.V. Operating Cashflow
Year Operating Cashflow Growth
2015 -1.213.414
2016 65.592.359 101.85%
2017 50.587.564 -29.66%
2018 52.788.898 4.17%
2019 21.203.346 -148.96%
2020 65.762.515 67.76%
2021 54.288.707 -21.13%
2022 85.305.384 36.36%
2023 94.187.754 9.43%
2024 11.530.434 -716.86%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genomma Lab Internacional, S.A.B. de C.V. Capital Expenditure
Year Capital Expenditure Growth
2015 7.410.472
2016 5.466.834 -35.55%
2017 15.912.754 65.64%
2018 76.789.700 79.28%
2019 46.420.302 -65.42%
2020 35.363.228 -31.27%
2021 40.744.881 13.21%
2022 21.658.242 -88.13%
2023 19.758.155 -9.62%
2024 4.076.078 -384.73%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genomma Lab Internacional, S.A.B. de C.V. Equity
Year Equity Growth
2015 535.498.607
2016 329.728.319 -62.41%
2017 360.260.049 8.47%
2018 377.165.402 4.48%
2019 422.267.951 10.68%
2020 443.775.764 4.85%
2021 490.436.828 9.51%
2022 520.518.675 5.78%
2023 552.415.058 5.77%
2024 576.723.354 4.21%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genomma Lab Internacional, S.A.B. de C.V. Assets
Year Assets Growth
2015 1.020.963.285
2016 762.498.653 -33.9%
2017 811.924.356 6.09%
2018 917.916.146 11.55%
2019 1.019.633.022 9.98%
2020 1.071.033.750 4.8%
2021 1.048.969.808 -2.1%
2022 1.107.766.793 5.31%
2023 1.216.553.377 8.94%
2024 1.198.612.059 -1.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genomma Lab Internacional, S.A.B. de C.V. Liabilities
Year Liabilities Growth
2015 485.464.677
2016 432.770.332 -12.18%
2017 451.664.307 4.18%
2018 540.750.743 16.47%
2019 597.365.070 9.48%
2020 627.257.985 4.77%
2021 558.532.979 -12.3%
2022 587.248.118 4.89%
2023 664.138.318 11.58%
2024 621.888.704 -6.79%

Genomma Lab Internacional, S.A.B. de C.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.02
Net Income per Share
0.08
Price to Earning Ratio
14.97x
Price To Sales Ratio
1.19x
POCF Ratio
17.7
PFCF Ratio
28.43
Price to Book Ratio
1.85
EV to Sales
1.5
EV Over EBITDA
4.43
EV to Operating CashFlow
23.98
EV to FreeCashFlow
35.7
Earnings Yield
0.07
FreeCashFlow Yield
0.04
Market Cap
1,15 Bil.
Enterprise Value
1,45 Bil.
Graham Number
1.02
Graham NetNet
-0.21

Income Statement Metrics

Net Income per Share
0.08
Income Quality
0.85
ROE
0.12
Return On Assets
0.07
Return On Capital Employed
0.22
Net Income per EBT
0.67
EBT Per Ebit
0.65
Ebit per Revenue
0.21
Effective Tax Rate
0.33

Margins

Sales, General, & Administrative to Revenue
5.32
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-0
Gross Profit Margin
0.64
Operating Profit Margin
0.21
Pretax Profit Margin
0.14
Net Profit Margin
0.09

Dividends

Dividend Yield
0.87
Dividend Yield %
87.45
Payout Ratio
0.64
Dividend Per Share
0.99

Operating Metrics

Operating Cashflow per Share
0.06
Free CashFlow per Share
0.04
Capex to Operating CashFlow
0.33
Capex to Revenue
0.02
Capex to Depreciation
1.17
Return on Invested Capital
0.35
Return on Tangible Assets
-0.02
Days Sales Outstanding
148.39
Days Payables Outstanding
98.86
Days of Inventory on Hand
142.92
Receivables Turnover
2.46
Payables Turnover
3.69
Inventory Turnover
2.55
Capex per Share
0.02

Balance Sheet

Cash per Share
0,06
Book Value per Share
0,61
Tangible Book Value per Share
-4.9
Shareholders Equity per Share
0.61
Interest Debt per Share
0.84
Debt to Equity
0.6
Debt to Assets
0.29
Net Debt to EBITDA
0.9
Current Ratio
1.96
Tangible Asset Value
-4,63 Bil.
Net Current Asset Value
0,03 Bil.
Invested Capital
5723265425
Working Capital
0,32 Bil.
Intangibles to Total Assets
4.35
Average Receivables
0,41 Bil.
Average Payables
0,11 Bil.
Average Inventory
142338641
Debt to Market Cap
0.3

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genomma Lab Internacional, S.A.B. de C.V. Dividends
Year Dividends Growth
2021 1
2022 1 0%
2023 1 0%
2024 1 0%

Genomma Lab Internacional, S.A.B. de C.V. Profile

About Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

CEO
Mr. Juan Marco Sparvieri
Employee
1.633
Address
Av. Antonio Dovalí Jaime no.70
Mexico City, 01210

Genomma Lab Internacional, S.A.B. de C.V. Executives & BODs

Genomma Lab Internacional, S.A.B. de C.V. Executives & BODs
# Name Age
1 Lic. Rodrigo Alonso Herrera Aspra
Founder & Chairman of the Board
70
2 Mr. Juan Marco Sparvieri
Chief Executive Officer
70
3 Engineer Antonio Zamora Galland
Executive Vice President of Finance & Administration and Chief Financial Officer
70
4 Ms. Christianne Ibáñez Garcia
Head of Investor Relations
70
5 Mr. Alejandro Bastón Patiño
EVice President of Institutional Relations, Media, HR & Sustainability
70
6 Mr. Efraan Tapia Cardova
Secretary
70
7 Daniel Suarez Neria
Investor Relations Officer
70

Genomma Lab Internacional, S.A.B. de C.V. Competitors